Human Longevity, Inc.
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Its core genomic sequencing and data-integration research is peer-reviewed and grounded in Craig Venter's well-established scientific track record, but the clinical benefit of its consumer whole-body screening products remains a debated question across preventive medicine generally, and its long-term corporate trajectory after Venter's 2018 departure and 2026 death is less independently documented.
Reference only. Not medical advice.
Human Longevity, Inc. is a genomics and precision medicine company that combines whole genome sequencing with advanced imaging, metabolomic, microbiomic, and proteomic data to build large-scale health datasets aimed at earlier detection of age-related disease, particularly cardiovascular disease, cancer, and dementia. Its founding premise, associated closely with Craig Venter's decades of genome sequencing work, was that integrating deep biological and clinical data on large cohorts of individuals, combined at the time with a stated interest in stem cell therapies, could identify disease risk long before symptoms appear and thereby extend healthy human lifespan. The company raised roughly 80 million dollars in a 2014 Series A round and pursued a further 220 million dollar Series B offering in 2016, along with a smaller 30 million dollar raise in 2019, and formed drug-development collaborations with pharmaceutical companies including Celgene and AstraZeneca. It has invested more than 600 million dollars cumulatively in its research and data infrastructure, sequencing genomes at industrial scale and building what it describes as one of the world's most comprehensive longitudinal health datasets, with over 75,000 genomes sequenced and more than 10,000 individual clients served through its clinical health-screening programs as of the mid-2020s. In January 2020 the company published a peer-reviewed study in the Proceedings of the National Academy of Sciences describing a cohort in which combining whole genome sequencing with metabolomics and advanced imaging identified previously undetected genetic and phenotypic disease risk in a meaningful share of healthy-seeming adult volunteers, and the company reports more than 20 peer-reviewed publications overall in venues including Nature Genetics and PNAS. Commercially, Human Longevity operates consumer and membership-based health-screening clinics offering whole genome sequencing, whole-body MRI, and extensive biomarker panels, positioning itself at the intersection of academic genomics research and direct-to-consumer preventive health services. Within the longevity field, the company is generally regarded as scientifically credible in its core genomics and data-generation work, reflecting Venter's established scientific reputation, while its consumer health-screening products, like most whole-body screening offerings, have drawn broader clinical debate over the value of comprehensive screening in asymptomatic populations, a debate that applies to the sector generally rather than being specific to the company.
Human Longevity, Inc. is a genomics and precision medicine company that combines whole genome sequencing with advanced imaging, metabolomic, microbiomic.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Founded in San Diego, California in 2013 and publicly announced on March 4, 2014, by genomics pioneer J. Craig Venter, physician-scientist Robert Hariri, and entrepreneur Peter Diamandis, with an initial goal of building the world's largest database of human genomic and phenotypic data. Venter, who had earlier led one of the first drafts of the human genome sequence and founded Celera Genomics and the J. Craig Venter Institute, served as chairman and CEO until stepping down in May 2018 amid a legal dispute with the company over trade secrets that was later dismissed; Venter died on April 29, 2026, at age 79, following treatment for cancer, and the company continues to operate under later leadership as of its most recent public statements.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Human Longevity, Inc.. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.